BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17555505)

  • 21. Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.
    Hesse E; Musholt PB; Potter E; Petrich T; Wehmeier M; von Wasielewski R; Lichtinghagen R; Musholt TJ
    Br J Cancer; 2005 Sep; 93(5):565-70. PubMed ID: 16091757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer.
    Hamy A; Mirallié E; Bennouna J; Resche I; Drefty C; Johnstone M; Visset J
    Eur J Surg Oncol; 2004 Aug; 30(6):681-5. PubMed ID: 15256244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing?
    Díaz-Soto G; Puig-Domingo M; Martínez-Pino I; Martínez de Osaba MJ; Mora M; Rivera-Fillat F; Halperin I
    Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):348-52. PubMed ID: 21264807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
    Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
    Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
    Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls.
    Spencer CA; Wang CC
    Endocrinol Metab Clin North Am; 1995 Dec; 24(4):841-63. PubMed ID: 8608781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?
    Zöphel K; Wunderlich G; Smith BR
    Thyroid; 2003 Sep; 13(9):861-5. PubMed ID: 14588100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
    Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
    Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
    Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
    Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
    Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
    Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
    Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
    Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
    Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
    Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
    Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
    Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
    Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
    Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
    Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
    Spencer C; Fatemi S; Singer P; Nicoloff J; Lopresti J
    Thyroid; 2010 Jun; 20(6):587-95. PubMed ID: 20470203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
    Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
    Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?
    Trimboli P; La Torre D; Ceriani L; Condorelli E; Laurenti O; Romanelli F; Ventura C; Signore A; Valabrega S; Giovanella L
    Horm Metab Res; 2013 Sep; 45(9):664-8. PubMed ID: 23720229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical significance of three-week thyroglobulin test in patients with thyroid cancer undergoing thyroidectomy].
    Vasil'ev DA; Poroshina TE; Radzhabova ZA; Bershteĭn LM
    Vopr Onkol; 2012; 58(4):481-5. PubMed ID: 23607201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.